A Bayesian Reanalysis of the Phase III Aducanumab (ADU) Trial
Authors:
- 31 May 2022
- journal article
- research article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 87 (3) , 1009-1012
Abstract
Background: In December 2019, in light of additional blinded data, Biogen claimed efficacy of the drug Aducanumab (ADU). Objective: We conducted a reanalysis of the phase III ADU summary statistics, focusing in particular on the Clinical Dementia Rating-Sum of Boxes. Methods: We used a Bayesian framework to mitigate the problems of the null-hypothesis significance testing framework. In particular, we used Bayes Factor (BF) to analyze the summary statistics. The BF is the comparison of how well two hypotheses predict the data. Results: Our results showed that the evidence for ADU efficacy is very low. The results show that the only data with a BF value in favor of the alternative hypothesis (i.e., drug efficacy) is the high-dose condition in the EMERGE trial. However, the obtained BF falls within the range of values considered anecdotal, meaning a low level of evidence. Conclusion: We provide a clearer interpretation of the results of the clinical trials based on the Bayesian framework, as this may be useful for future development and research in the field.Keywords
All Related Versions
This publication has 4 references indexed in Scilit:
- Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019Alzheimer's & Dementia, 2020
- A Bayes factor meta-analysis of Bem’s ESP claimPsychonomic Bulletin & Review, 2011
- Bayesian t tests for accepting and rejecting the null hypothesisPsychonomic Bulletin & Review, 2009
- Toward Evidence-Based Medical Statistics. 2: The Bayes FactorAnnals of Internal Medicine, 1999